{
    "organizations": [],
    "uuid": "89e2e22aa86839f04e2ce749302f1e0d7b7a3457",
    "author": "",
    "url": "https://www.reuters.com/article/brief-dynasil-announces-submission-of-xc/brief-dynasil-announces-submission-of-xcede-technologies-application-for-first-in-human-clinical-trial-idUSASB0C0RQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Dynasil Announces Submission Of Xcede Technologies' Application For First-In-Human Clinical Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 11, 2018 / 9:43 PM / Updated 11 minutes ago BRIEF-Dynasil Announces Submission Of Xcede Technologies' Application For First-In-Human Clinical Trial Reuters Staff \nJan 11 (Reuters) - Dynasil Corporation Of America: \n* DYNASIL ANNOUNCES SUBMISSION OF XCEDE TECHNOLOGIES’ APPLICATION FOR FIRST-IN-HUMAN CLINICAL TRIAL \n* DYNASIL CORPORATION OF AMERICA - ‍ANTICIPATES THAT PATIENTS WILL BE TREATED WITH XCEDE PATCH IN NETHERLANDS IN EARLY 2018​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-11T23:42:00.000+02:00",
    "crawled": "2018-01-11T23:58:06.022+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "submission",
        "xcede",
        "technology",
        "application",
        "clinical",
        "trial",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "dynasil",
        "corporation",
        "america",
        "dynasil",
        "announces",
        "submission",
        "xcede",
        "technology",
        "application",
        "clinical",
        "trial",
        "dynasil",
        "corporation",
        "america",
        "patient",
        "treated",
        "xcede",
        "patch",
        "netherlands",
        "early",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}